Orna Therapeutics Raises $221M for RNA Tech Advancement
Orna Therapeutics has raised $221 million in a Series B funding round, announced on August 16, 2022. The company, specialising in RNA therapeutics, will use the funds to advance its circular lipid nanoparticle delivery platform and expand its reach.
The funding round was led by Merck, with participation from founding investors MPM Capital and BioImpact Capital. Orna Therapeutics has also entered into a collaboration agreement with Merck to further develop its innovative technology.
Law firms Cooley LLP and Gunderson Dettmer represented the investors Rosemary G. Reilly, Rebecca Nauta, Jenna Ventorino, Nick Andreacchi, Meghan Walsh, and Bill Caporizzo in this round. The funds will support Orna's continued research and development, enabling it to push the boundaries of RNA therapeutics.
Orna Therapeutics' Series B funding round has brought in $221 million, with Merck as the lead investor and collaborator. The company will use these funds to advance its delivery platform and expand its RNA therapeutic offerings, marking a significant step forward in the field.
Read also:
- Unveiling the Less-Discussed Disadvantages of Buds - Revealing the Silent Story
- Grid Risk Evaluation Strategy By NERC Outlined, Focusing on Potential Threats from Data Centers
- Rapid Expansion in Organic Rice Protein Market Projected at 15.6% Through 2034
- Vantor & Lanteris Fuel US Intelligence with Innovative Tech
